Malignant Mesothelioma - Pipeline Review, H1 2015

Transcription

1 Brochure More information from Malignant Mesothelioma - Pipeline Review, H Description: Malignant Mesothelioma - Pipeline Review, H Summary This, Malignant Mesothelioma - Pipeline Review, H1 2015, provides an overview of the Malignant Mesothelioma s therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Malignant Mesothelioma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Malignant Mesothelioma and special features on late-stage and discontinued projects. This report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from This proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by This team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in -class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides a snapshot of the global therapeutic landscape of Malignant Mesothelioma - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Malignant Mesothelioma and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Malignant Mesothelioma products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Malignant Mesothelioma pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Malignant Mesothelioma - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline

2 - Devise corrective measures for pipeline projects by understanding Malignant Mesothelioma pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Contents: List of Tables List of Figures Introduction REPORT COVERAGE Malignant Mesothelioma Overview Therapeutics Development Pipeline Products for Malignant Mesothelioma - Overview Pipeline Products for Malignant Mesothelioma - Comparative Analysis Malignant Mesothelioma - Therapeutics under Development by Companies Malignant Mesothelioma - Therapeutics under Investigation by Universities/Institutes Malignant Mesothelioma - Pipeline Products Glance Late Stage Products Clinical Stage Products Early Stage Products Unknown Stage Products Malignant Mesothelioma - Products under Development by Companies Malignant Mesothelioma - Products under Investigation by Universities/Institutes Malignant Mesothelioma - Companies Involved in Therapeutics Development Aduro BioTech, Inc. Advantagene, Inc. Aeolus Pharmaceuticals, Inc. Amphera BV Applied Research using OMIC Sciences, S.L. argen-x BV ArQule, Inc. AVEO Pharmaceuticals, Inc. Bayer AG Biogen, Inc. Bionomics Limited Biotecnol, Inc. Boehringer Ingelheim GmbH Boston Biomedical, Inc. Bristol-Myers Squibb Company Calithera Biosciences, Inc. CanBas Co., Ltd. Concordia Healthcare Corp. CritiTech, Inc. Deciphera Pharmaceuticals, LLC Eagle Pharmaceuticals, Inc. Eisai Co., Ltd. Eli Lilly and Company EnGeneIC Ltd F. Hoffmann-La Roche Ltd. Five Prime Therapeutics, Inc. Formula Pharmaceuticals, Inc. Genelux Corporation GlaxoSmithKline plc Juno Therapeutics Inc. Kyowa Hakko Kirin Co., Ltd. MedImmune, LLC Merck & Co., Inc. Merck KGaA Millennium Pharmaceuticals, Inc. MolMed S.p.A. Morphotek, Inc.

3 Novartis AG Oncos Therapeutics Ltd. Oxford BioMedica plc Pfizer Inc. Pharma Mar, S.A. Polaris Pharmaceuticals, Inc. Sellas Inc. SentoClone International AB Synta Pharmaceuticals Corp. VasGene Therapeutics, Inc. Verastem, Inc. Virttu Biologics Limited Y's Therapeutics Co., Ltd. Malignant Mesothelioma - Therapeutics Assessment Assessment by Monotherapy Products Assessment by Combination Products Assessment by Target Assessment by Mechanism of Action Assessment by Route of Administration Assessment by Molecule Type Drug Profiles AEOL Drug Profile alisertib - Drug Profile amatuximab - Drug Profile anetumab ravtansine - Drug Profile ARGX Drug Profile ascrinvacumab - Drug Profile AV Drug Profile avelumab - Drug Profile BERTA - Drug Profile BG Drug Profile BIW Drug Profile BMS Drug Profile BNC Drug Profile CB Drug Profile CBP Drug Profile Cell Therapy 1 for Oncology - Drug Profile CRS Drug Profile defactinib hydrochloride - Drug Profile Dendritic Cell Therapy for Cancer - Drug Profile Dendritic Cell Therapy for Oncology and Infectious Disease - Drug Profile DP Drug Profile DPV Drug Profile E Drug Profile FP Drug Profile FPI-01 - Drug Profile ganetespib - Drug Profile Gene Therapy for Malignant Pleural Mesothelioma - Drug Profile Gene Therapy to Activate NK4 for Malignant Pleural Mesothelioma - Drug Profile GLONC-1 - Drug Profile GSK Drug Profile HSV Drug Profile icasp9m28z - Drug Profile JTCR Drug Profile LY Drug Profile MesoCancerVac - Drug Profile MesoCART - Drug Profile Monoclonal Antibody Conjugated to Target Mesothelin for Oncology - Drug Profile MV-NIS - Drug Profile napabucasin - Drug Profile NGR-hTNF - Drug Profile nintedanib - Drug Profile ONCOS Drug Profile

4 Oshadi D + Oshadi R - Drug Profile paclitaxel - Drug Profile pegargiminase - Drug Profile pembrolizumab - Drug Profile pemetrexed disodium - Drug Profile porfimer sodium - Drug Profile Recombinant Protein to Antagonize EphB4 Receptor for Oncology - Drug Profile RG Drug Profile Sentoclone - Drug Profile Small Molecules to Inhibit Bcl-2 Survival Proteins for Cancer - Drug Profile Stem Cell Therapy to Target TRAIL Receptor for Malignant Pleural Mesothelioma and Mestatic Lung Cancer - Drug Profile TargomiRs - Drug Profile Tb Drug Profile tivantinib - Drug Profile trabectedin - Drug Profile tremelimumab - Drug Profile TroVax - Drug Profile Vaccine for Cancer - Drug Profile Vaccine For Oncolytic Newcastle Disease Virus - Drug Profile Vaccine to Target WT1 for Cancer - Drug Profile VS Drug Profile YS Drug Profile Malignant Mesothelioma - Recent Pipeline Updates Malignant Mesothelioma - Dormant Projects Malignant Mesothelioma - Discontinued Products Malignant Mesothelioma - Product Development Milestones Featured News & Press Releases Appendix Methodology Coverage Secondary Research Primary Research Expert Panel Validation Contact Us Disclaimer List of Tables Number of Products under Development for Malignant Mesothelioma, H Number of Products under Development for Malignant Mesothelioma - Comparative Analysis, H Number of Products under Development by Companies, H Number of Products under Development by Companies, H (Contd..1) Number of Products under Development by Companies, H (Contd..2) Number of Products under Development by Companies, H (Contd..3) Number of Products under Investigation by Universities/Institutes, H Comparative Analysis by Late Stage Development, H Comparative Analysis by Clinical Stage Development, H Comparative Analysis by Early Stage Development, H Comparative Analysis by Unknown Stage Development, H Products under Development by Companies, H Products under Development by Companies, H (Contd..1) Products under Development by Companies, H (Contd..2) Products under Development by Companies, H (Contd..3) Products under Investigation by Universities/Institutes, H Malignant Mesothelioma - Pipeline by Aduro BioTech, Inc., H Malignant Mesothelioma - Pipeline by Advantagene, Inc., H Malignant Mesothelioma - Pipeline by Aeolus Pharmaceuticals, Inc., H Malignant Mesothelioma - Pipeline by Amphera BV, H Malignant Mesothelioma - Pipeline by Applied Research using OMIC Sciences, S.L., H Malignant Mesothelioma - Pipeline by argen-x BV, H Malignant Mesothelioma - Pipeline by ArQule, Inc., H Malignant Mesothelioma - Pipeline by AVEO Pharmaceuticals, Inc., H Malignant Mesothelioma - Pipeline by Bayer AG, H1 2015

5 Malignant Mesothelioma - Pipeline by Biogen, Inc., H Malignant Mesothelioma - Pipeline by Bionomics Limited, H Malignant Mesothelioma - Pipeline by Biotecnol, Inc., H Malignant Mesothelioma - Pipeline by Boehringer Ingelheim GmbH, H Malignant Mesothelioma - Pipeline by Boston Biomedical, Inc., H Malignant Mesothelioma - Pipeline by Bristol-Myers Squibb Company, H Malignant Mesothelioma - Pipeline by Calithera Biosciences, Inc., H Malignant Mesothelioma - Pipeline by CanBas Co., Ltd., H Malignant Mesothelioma - Pipeline by Concordia Healthcare Corp., H Malignant Mesothelioma - Pipeline by CritiTech, Inc., H Malignant Mesothelioma - Pipeline by Deciphera Pharmaceuticals, LLC, H Malignant Mesothelioma - Pipeline by Eagle Pharmaceuticals, Inc., H Malignant Mesothelioma - Pipeline by Eisai Co., Ltd., H Malignant Mesothelioma - Pipeline by Eli Lilly and Company, H Malignant Mesothelioma - Pipeline by EnGeneIC Ltd, H Malignant Mesothelioma - Pipeline by F. Hoffmann-La Roche Ltd., H Malignant Mesothelioma - Pipeline by Five Prime Therapeutics, Inc., H Malignant Mesothelioma - Pipeline by Formula Pharmaceuticals, Inc., H Malignant Mesothelioma - Pipeline by Genelux Corporation, H Malignant Mesothelioma - Pipeline by GlaxoSmithKline plc, H Malignant Mesothelioma - Pipeline by Juno Therapeutics Inc., H Malignant Mesothelioma - Pipeline by Kyowa Hakko Kirin Co., Ltd., H Malignant Mesothelioma - Pipeline by MedImmune, LLC, H Malignant Mesothelioma - Pipeline by Merck & Co., Inc., H Malignant Mesothelioma - Pipeline by Merck KGaA, H Malignant Mesothelioma - Pipeline by Millennium Pharmaceuticals, Inc., H Malignant Mesothelioma - Pipeline by MolMed S.p.A., H Malignant Mesothelioma - Pipeline by Morphotek, Inc., H Malignant Mesothelioma - Pipeline by Novartis AG, H Malignant Mesothelioma - Pipeline by Oncos Therapeutics Ltd., H Malignant Mesothelioma - Pipeline by Oxford BioMedica plc, H Malignant Mesothelioma - Pipeline by Pfizer Inc., H Malignant Mesothelioma - Pipeline by Pharma Mar, S.A., H Malignant Mesothelioma - Pipeline by Polaris Pharmaceuticals, Inc., H Malignant Mesothelioma - Pipeline by Sellas Inc., H Malignant Mesothelioma - Pipeline by SentoClone International AB, H Malignant Mesothelioma - Pipeline by Synta Pharmaceuticals Corp., H Malignant Mesothelioma - Pipeline by VasGene Therapeutics, Inc., H Malignant Mesothelioma - Pipeline by Verastem, Inc., H Malignant Mesothelioma - Pipeline by Virttu Biologics Limited, H Malignant Mesothelioma - Pipeline by Y's Therapeutics Co., Ltd., H Assessment by Monotherapy Products, H Assessment by Combination Products, H Number of Products by Stage and Target, H Number of Products by Stage and Mechanism of Action, H Number of Products by Stage and Route of Administration, H Number of Products by Stage and Molecule Type, H Malignant Mesothelioma Therapeutics - Recent Pipeline Updates, H Malignant Mesothelioma - Dormant Projects, H Malignant Mesothelioma - Dormant Projects (Contd..1), H Malignant Mesothelioma - Discontinued Products, H List of Figures Number of Products under Development for Malignant Mesothelioma, H Number of Products under Development for Malignant Mesothelioma - Comparative Analysis, H Number of Products under Development by Companies, H Number of Products under Investigation by Universities/Institutes, H Comparative Analysis by Clinical Stage Development, H Comparative Analysis by Early Stage Products, H Assessment by Monotherapy Products, H Number of Products by Top 10 Targets, H Number of Products by Stage and Top 10 Targets, H Number of Products by Top 10 Mechanism of Actions, H1 2015

6 Number of Products by Stage and Top 10 Mechanism of Actions, H Number of Products by Top 10 Routes of Administration, H Number of Products by Stage and Top 10 Routes of Administration, H Number of Products by Top 10 Molecule Types, H Number of Products by Stage and Top 10 Molecule Types, H Ordering: Order Online - Order by Fax - using the form below Order by Post - print the order form below and send to Research and Markets, Guinness Centre, Taylors Lane, Dublin 8, Ireland.

7 Page 1 of 2 Fax Order Form To place an order via fax simply print this form, fill in the information below and fax the completed form to (from USA) or (from Rest of World). If you have any questions please visit Order Information Please verify that the product information is correct and select the format(s) you require. Product Name: Malignant Mesothelioma - Pipeline Review, H Web Address: Office Code: Product Formats Please select the product formats and quantity you require: SC Electronic (PDF) - Single User: Electronic (PDF) - Site License: Electronic (PDF) - Enterprisewide: Quantity USD 2000 USD 4000 USD 6000 Contact Information Please enter all the information below in BLOCK CAPITALS Title: Mr Mrs Dr Miss Ms Prof First Name: Last Name: Address: * Job Title: Organisation: Address: City: Postal / Zip Code: Country: Phone Number: Fax Number: * Please refrain from using free accounts when ordering (e.g. Yahoo, Hotmail, AOL)

8 Page 2 of 2 Payment Information Please indicate the payment method you would like to use by selecting the appropriate box. Pay by credit card: You will receive an with a link to a secure webpage to enter your credit card details. Pay by check: Please post the check, accompanied by this form, to: Research and Markets, Guinness Center, Taylors Lane, Dublin 8, Ireland. Pay by wire transfer: Please transfer funds to: Account number Sort code Swift code IBAN number Bank Address ULSBIE2D IE78ULSB Ulster Bank, Main Street, Blackrock, Co. Dublin, Ireland. If you have a Marketing Code please enter it below: Marketing Code: Please note that by ordering from Research and Markets you are agreeing to our Terms and Conditions at Please fax this form to: (646) or (646) From USA or From Rest of World